Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2018-10-31

FDA Approved: BUPRENORPHINE — Supplemental Application (Actavis Pharma, Inc.)

View source ↗

Summary

FDA approved a supplemental application for buprenorphine submitted by Actavis Pharma, Inc. under ANDA090819. The action confirms approval of changes allowed by…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • buprenorphine (buprenorphine)

Snippet

SUPPL AP for BUPRENORPHINE (BUPRENORPHINE)